me by phone. The seven San Diego IPOs accounted for more than half of 13 life sciences deals in the West, according to EY.
Healthcare was the most active sector for IPO activity, with 52 companies raising a total of more than $8.5 billion, according to Renaissance Capital. While there has been a recent slowdown in life sciences IPOs, Regnier says he believes IPO activity will resume following the annual J.P. Morgan Healthcare Conference in San Francisco next month.
EY also maintains that overall IPO activity should remain strong in 2014, with a backlog of 76 deals in the IPO pipeline carrying over for a strong start in the New Year. “Investors have had the opportunity to engage with a variety of companies in the pipeline and their appetite for risk has returned,” said Jackie Kelley, an EY partner in Irvine, CA, who leads the firm’s IPO advisory services in the Americas. “VC-backed companies came back to market and PE-backed IPOs will continue to push into 2014.”
Looking deeper into 2014, EY says the future looks bright, with more companies in Europe, the Middle East, and South America looking to list on the U.S. markets—attracted by high valuations and good post-IPO performances over the past year.
“IPOs in 2014 will be a combination of household names, as well as disruptive, innovative companies,” Kelley says. “The backlog of PE-backed IPOs will continue to push into 2014 and companies blurred by sector convergence will drive market activity, all making for another exciting year.”